Drug Development Management
BC-1510
Level 1
Pharmaceuticals & Life Sciences
0 providers
0 API surfaces
Preclinical and clinical development across phases.
Drug Development Management (BC-1510) is a level-1 business capability in the Pharmaceuticals & Life Sciences model. The catalog holds 0 API surface(s) from 0 provider(s) that can perform some part of it. Reach is the vendor surface that lands on this capability — it is not a claim about what any particular organisation has deployed.
Where this capability definition comes from.
This capability is part of a published business-architecture model that API Evangelist
did not author. It is redistributed here under
CC-BY-4.0.
Turbo EA Capabilities by Vincent Verdet — Turbo EA, https://github.com/vincentmakes/turbo-ea-capabilities, CC BY 4.0
Changes: Consolidated from 333 per-L1 YAML files into one JSON; English only (upstream i18n/ omitted); descriptions whitespace-normalised. No capability was added, removed, renamed or re-parented.
Source repository · NOTICE and third-party framework attributions
Sub-capabilities
Pre-Clinical Development Management BC-1510.10
Pre-clinical pharmacology, toxicology, ADME.
no catalog coverage
Phase I Clinical Development Management BC-1510.20
First-in-human, safety, PK/PD.
no catalog coverage
Phase II Clinical Development Management BC-1510.30
Proof of concept, dose-finding.
no catalog coverage
Phase III Clinical Development Management BC-1510.40
Pivotal trials, registration studies.
no catalog coverage
Phase IV / Post-Marketing Development Management BC-1510.50
Post-marketing studies, real-world evidence.
no catalog coverage
CMC Development Management BC-1510.60
Chemistry, manufacturing, controls development.
no catalog coverage
Providers that reach this capability
No provider in the catalog currently publishes an API surface that reaches
this capability. That is a real answer, not a gap in the page: much of what an enterprise does
runs on internal systems that publish no API at all.
This page carries no rating. Capabilities are not rated. A capability is a description of what a business does, not a thing a company publishes, so a Kin Score would have nothing to measure.
The edge table is a Pro feature.
This page shows
which providers and tags reach Drug Development Management. The underlying
tag → capability edges — each with the quoted fragment of the provider's own
OpenAPI that evidences it, a calibrated confidence score, and the contract-provenance gate
it passed — are available through the API, along with company-level capability maps.
Only edges at confidence ≥ 0.7 with evidence found verbatim in
the source contract are published at all.
See plans →
·
How the edges are graded →